An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping

Hubert Lau, Alexandra Nagy, Susan K. Atwater, Michael Cascio, Robert S. Ohgami

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: CD13 is a myeloid associated antigen, which may be expressed by a subset of B cell lymphomas; however, the significance of its expression along with other B cell associated antigens is not well characterized. Methods: Two hundred and eighty-six mature B cell neoplasms with flow cytometric analysis performed at the time of diagnosis were identified. Expression of CD13, CD45, CD19, CD20, CD5, CD10, CD38, CD22, CD23, FMC7, and kappa and lambda light chains was assessed for each case and correlated with clinicopathologic features. Results: CD13 expression was associated specifically with cases of lymphoplasmacytic lymphoma (LPL) (16/26)- and FMC7-positive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (11/30). No cases of follicular lymphoma (FL) expressed CD13 (0/48). Across all B cell neoplasms, CD13 expression positively correlated with FMC7 co-expression and kappa light chain restriction and negatively correlated with CD10 co-expression and lambda light chain restriction. No significant association of CD13 with overall or disease free survival in B cell neoplasms was seen. Conclusion: CD13 expression is present more often in LPL- and FMC7-positive CLL/SLL than other mature B cell lymphoma subtypes and absent in cases of FL and may be a useful feature for diagnostic subtyping.

Original languageEnglish (US)
JournalInternational Journal of Laboratory Hematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Flow cytometry
B-Cell Chronic Lymphocytic Leukemia
Flow Cytometry
B-Lymphocytes
Cells
Follicular Lymphoma
B-Cell Lymphoma
Light
Lymphoma
Neoplasms
Antigens
Disease-Free Survival

Keywords

  • B cell lymphoma
  • CD13
  • Flow cytometry

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping. / Lau, Hubert; Nagy, Alexandra; Atwater, Susan K.; Cascio, Michael; Ohgami, Robert S.

In: International Journal of Laboratory Hematology, 01.01.2018.

Research output: Contribution to journalArticle

@article{736e0c9ee70d4883892dc395e9572928,
title = "An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping",
abstract = "Introduction: CD13 is a myeloid associated antigen, which may be expressed by a subset of B cell lymphomas; however, the significance of its expression along with other B cell associated antigens is not well characterized. Methods: Two hundred and eighty-six mature B cell neoplasms with flow cytometric analysis performed at the time of diagnosis were identified. Expression of CD13, CD45, CD19, CD20, CD5, CD10, CD38, CD22, CD23, FMC7, and kappa and lambda light chains was assessed for each case and correlated with clinicopathologic features. Results: CD13 expression was associated specifically with cases of lymphoplasmacytic lymphoma (LPL) (16/26)- and FMC7-positive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (11/30). No cases of follicular lymphoma (FL) expressed CD13 (0/48). Across all B cell neoplasms, CD13 expression positively correlated with FMC7 co-expression and kappa light chain restriction and negatively correlated with CD10 co-expression and lambda light chain restriction. No significant association of CD13 with overall or disease free survival in B cell neoplasms was seen. Conclusion: CD13 expression is present more often in LPL- and FMC7-positive CLL/SLL than other mature B cell lymphoma subtypes and absent in cases of FL and may be a useful feature for diagnostic subtyping.",
keywords = "B cell lymphoma, CD13, Flow cytometry",
author = "Hubert Lau and Alexandra Nagy and Atwater, {Susan K.} and Michael Cascio and Ohgami, {Robert S.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/ijlh.12909",
language = "English (US)",
journal = "International Journal of Laboratory Hematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - An integrated flow cytometry analysis of 286 mature B cell neoplasms identifies CD13 as a useful marker for diagnostic subtyping

AU - Lau, Hubert

AU - Nagy, Alexandra

AU - Atwater, Susan K.

AU - Cascio, Michael

AU - Ohgami, Robert S.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: CD13 is a myeloid associated antigen, which may be expressed by a subset of B cell lymphomas; however, the significance of its expression along with other B cell associated antigens is not well characterized. Methods: Two hundred and eighty-six mature B cell neoplasms with flow cytometric analysis performed at the time of diagnosis were identified. Expression of CD13, CD45, CD19, CD20, CD5, CD10, CD38, CD22, CD23, FMC7, and kappa and lambda light chains was assessed for each case and correlated with clinicopathologic features. Results: CD13 expression was associated specifically with cases of lymphoplasmacytic lymphoma (LPL) (16/26)- and FMC7-positive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (11/30). No cases of follicular lymphoma (FL) expressed CD13 (0/48). Across all B cell neoplasms, CD13 expression positively correlated with FMC7 co-expression and kappa light chain restriction and negatively correlated with CD10 co-expression and lambda light chain restriction. No significant association of CD13 with overall or disease free survival in B cell neoplasms was seen. Conclusion: CD13 expression is present more often in LPL- and FMC7-positive CLL/SLL than other mature B cell lymphoma subtypes and absent in cases of FL and may be a useful feature for diagnostic subtyping.

AB - Introduction: CD13 is a myeloid associated antigen, which may be expressed by a subset of B cell lymphomas; however, the significance of its expression along with other B cell associated antigens is not well characterized. Methods: Two hundred and eighty-six mature B cell neoplasms with flow cytometric analysis performed at the time of diagnosis were identified. Expression of CD13, CD45, CD19, CD20, CD5, CD10, CD38, CD22, CD23, FMC7, and kappa and lambda light chains was assessed for each case and correlated with clinicopathologic features. Results: CD13 expression was associated specifically with cases of lymphoplasmacytic lymphoma (LPL) (16/26)- and FMC7-positive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (11/30). No cases of follicular lymphoma (FL) expressed CD13 (0/48). Across all B cell neoplasms, CD13 expression positively correlated with FMC7 co-expression and kappa light chain restriction and negatively correlated with CD10 co-expression and lambda light chain restriction. No significant association of CD13 with overall or disease free survival in B cell neoplasms was seen. Conclusion: CD13 expression is present more often in LPL- and FMC7-positive CLL/SLL than other mature B cell lymphoma subtypes and absent in cases of FL and may be a useful feature for diagnostic subtyping.

KW - B cell lymphoma

KW - CD13

KW - Flow cytometry

UR - http://www.scopus.com/inward/record.url?scp=85051012090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051012090&partnerID=8YFLogxK

U2 - 10.1111/ijlh.12909

DO - 10.1111/ijlh.12909

M3 - Article

C2 - 30066366

AN - SCOPUS:85051012090

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-5521

ER -